Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020112460 - A METHOD OF TREATING REFRACTORY EPILEPSY SYNDROMES USING FENFLURAMINE ENANTIOMERS

Publication Number WO/2020/112460
Publication Date 04.06.2020
International Application No. PCT/US2019/062432
International Filing Date 20.11.2019
IPC
C09K 19/38 2006.01
CCHEMISTRY; METALLURGY
09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
KMATERIALS FOR APPLICATIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
19Liquid crystal materials
04characterised by the chemical structure of the liquid crystal components
38Polymers, e.g. polyamides
C09K 19/58 2006.01
CCHEMISTRY; METALLURGY
09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
KMATERIALS FOR APPLICATIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
19Liquid crystal materials
52characterised by components which are not liquid crystals, e.g. additives
58Dopants or charge transfer agents
G02B 5/30 2006.01
GPHYSICS
02OPTICS
BOPTICAL ELEMENTS, SYSTEMS, OR APPARATUS
5Optical elements other than lenses
30Polarising elements
CPC
C09K 19/38
CCHEMISTRY; METALLURGY
09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
19Liquid crystal materials
04characterised by the chemical structure of the liquid crystal components ; , e.g. by a specific unit
38Polymers
C09K 19/58
CCHEMISTRY; METALLURGY
09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
19Liquid crystal materials
52characterised by components which are not liquid crystals, e.g. additives ; with special physical aspect: solvents, solid particles
58Dopants or charge transfer agents
G02B 5/30
GPHYSICS
02OPTICS
BOPTICAL ELEMENTS, SYSTEMS, OR APPARATUS
5Optical elements other than lenses
30Polarising elements
Applicants
  • ZOGENIX INTERNATIONAL LIMITED [GB]/[GB]
  • MARTIN, Parthena [US]/[US]
Inventors
  • MARTIN, Parthena
Agents
  • BOZICEVIC, Karl
Priority Data
62/773,84630.11.2018US
62/848,96916.05.2019US
62/854,79430.05.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) A METHOD OF TREATING REFRACTORY EPILEPSY SYNDROMES USING FENFLURAMINE ENANTIOMERS
(FR) PROCÉDÉ DE TRAITEMENT DE SYNDROMES D'ÉPILEPSIE RÉFRACTAIRE À L'AIDE D'ÉNANTIOMÈRES DE FENFLURAMINE
Abstract
(EN)
Methods of treating intractable epilepsy syndromes by administering a therapeutically effective dose of a therapeutic agent consisting essentially of a single fenfluramine enantiomer which can be either levofenfluramine or dexfenfluramine, are provided. Intractable epilepsy syndromes for which the present invention finds use include but are not limited to Dravet syndrome, Lennox-Gastaut syndrome, Doose syndrome, West syndrome and refractory seizures. Also provided are methods of treating a neurodegenerative disease in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.
(FR)
L'invention concerne des procédés de traitement de syndromes d'épilepsie rebelles par l'administration d'une dose thérapeutiquement efficace d'un agent thérapeutique essentiellement constitué d'un seul énantiomère de fenfluramine qui peut être soit la lévofenfluramine, soit la dexfenfluramine. Les syndromes d'épilepsie rebelles pour lesquels la présente invention trouve une utilisation comprennent, mais sans s'y limiter, le syndrome de Dravet, le syndrome de Lennox-Gastaut, le syndrome de Doose, le syndrome de West et les crises épileptiques réfractaires. L'invention concerne également des procédés de traitement d'une maladie neurodégénérative chez un sujet qui en a besoin. L'invention concerne également des compositions pharmaceutiques destinées à être utilisées dans la mise en œuvre des procédés de l’invention.
Latest bibliographic data on file with the International Bureau